Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Britta A P Laros-van Gorkom"'
Autor:
Ferdows Atiq, Johan Boender, Waander L. van Heerde, Juan M. Tellez Garcia, Selene C. Schoormans, Sandy Krouwel, Marjon H. Cnossen, Britta A. P. Laros-van Gorkom, Joke de Meris, Karin Fijnvandraat, Johanna G. van der Bom, Karina Meijer, Karin P. M. van Galen, Jeroen Eikenboom, Frank W. G. Leebeek, for the WiN Study Group
Publikováno v:
HemaSphere, Vol 6, Iss 6, p e718 (2022)
Genotyping is not routinely performed at diagnosis of von Willebrand disease (VWD). Therefore, the association between genetic variants and pathogenic mechanism or the clinical and laboratory phenotype is unknown in most patients, especially in type
Externí odkaz:
https://doaj.org/article/b94cb49d3709414589c99a1f377839d1
Autor:
Lars L. F. G. Valke, Danielle Meijer, Laurens Nieuwenhuizen, Britta A. P. Laros‐van Gorkom, Nicole M. A. Blijlevens, Waander L. vanHeerde, Saskia E. M. Schols
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 2, Pp n/a-n/a (2022)
Abstract Introduction Analysis of fibrinolytic disorders is challenging and may potentially lead to underdiagnosis of patients with an increased bleeding tendency. Aim To compare clinical characteristics, laboratory measurements, and treatment modali
Externí odkaz:
https://doaj.org/article/1aaa3b7a8b554993927dd62d5d67e237
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 2, Pp 343-346 (2020)
Abstract Congenital afibrinogenemia is a rare autosomal recessive disorder associated with an increased risk of hemorrhage, thrombosis, and obstetric complications. This case series of 4 pregnancies in 2 related patients seeks to address the key clin
Externí odkaz:
https://doaj.org/article/3bef03e1142e47bf9f4ed025c359d642
Autor:
Johan Boender, Ferdows Atiq, Marjon H. Cnossen, Johanna G. van der Bom, Karin Fijnvandraat, Joke de Meris, Moniek P. M. de Maat, Karin P. M. van Galen, Britta A. P. Laros-van Gorkom, Karina Meijer, Jeroen Eikenboom, Frank W. G. Leebeek, for the WiN study group
Publikováno v:
HemaSphere, Vol 5, Iss 3, p e542 (2021)
Von Willebrand factor (VWF) multimer analysis is important in the classification of von Willebrand disease (VWD). Current visual VWF multimer analysis is time consuming and inaccurate in detecting subtle changes in multimer patterns. Although VWF mul
Externí odkaz:
https://doaj.org/article/9417f6e0e8384b96a65c589f3b60f36d
Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial)
Autor:
Iris van Moort, Tim Preijers, Laura H Bukkems, Hendrika C A M Hazendonk, Johanna G van der Bom, Britta A P Laros-van Gorkom, Erik A M Beckers, Laurens Nieuwenhuizen, Felix J M van der Meer, Paula Ypma, Michiel Coppens, Karin Fijnvandraat, Roger E G Schutgens, Karina Meijer, Frank W G Leebeek, Ron A A Mathôt, Marjon H Cnossen, Marjon H. Cnossen, Frank W.G. Leebeek, Ron A.A. Mathôt, Marieke J.H.A. Kruip, Suzanne Polinder, Janske Lock, Hendrika C.A.M. Hazendonk, Iris Van Moort, Jessica M. Heijdra, Marie C.H.J. Goedhart, Wala Al Arashi, Nico C.B. De Jager, Laura H. Bukkems, Michael E. Cloesmeijer, Alexander Janssen, Rienk Y.J. Tamminga, Paul Brons, Saskia E.M. Schols, Jeroen C.J. Eikenboom, Felix J.M. Van der Meer, Roger E.G. Schutgens, Kathelijne Fischer, Karin P.M. Van Galen, Erik E.A.M. Beckers, Floor C.J.I. Heubel-Moenen, Mariëtte H.E. Driessens, Ineke Van Vliet, Peter W. Collins, Ri Liesner, Pratima Chowdary, Carolyn M. Millar, Dan Hart, David Keeling
Publikováno v:
The Lancet Haematology, 8(7), e492-e502. Lancet Publishing Group
Lancet. Haematology, 8(7), e492-e502. Lancet Publishing Group
Lancet Haematology, 8, e492-e502
Lancet Haematology, 8(7), E492-E502. ELSEVIER SCI LTD
The Lancet Haematology, 8(7), E492-E502. ELSEVIER SCI LTD
Lancet Haematology, 8, 7, pp. e492-e502
Lancet. Haematology, 8(7), e492-e502. Lancet Publishing Group
Lancet Haematology, 8, e492-e502
Lancet Haematology, 8(7), E492-E502. ELSEVIER SCI LTD
The Lancet Haematology, 8(7), E492-E502. ELSEVIER SCI LTD
Lancet Haematology, 8, 7, pp. e492-e502
Contains fulltext : 237493.pdf (Publisher’s version ) (Closed access) BACKGROUND: Dosing of replacement therapy with factor VIII concentrate in patients with haemophilia A in the perioperative setting is challenging. Underdosing and overdosing of f
Autor:
Nicole M. A. Blijlevens, Wideke Barteling, Waander L. van Heerde, Laura H. Bukkems, Britta A P Laros-van Gorkom, Ron A. A. Mathôt, Lars L F G Valke, Saskia E M Schols
Publikováno v:
Journal of thrombosis and haemostasis, 18(12), 3222-3231. Wiley-Blackwell
Thrombosis and Haemostasis, 18, 3222-3231
Journal of Thrombosis and Haemostasis
Thrombosis and Haemostasis, 18, 12, pp. 3222-3231
Thrombosis and Haemostasis, 18, 3222-3231
Journal of Thrombosis and Haemostasis
Thrombosis and Haemostasis, 18, 12, pp. 3222-3231
Background Clinical severity of hemophilia A (HA) varies, possibly due to interplay of many factors in the hemostatic pathway. Pharmacokinetic monitoring of factor VIII (FVIII) replacement therapy in HA patients consists of measuring FVIII activity l
Autor:
Annet Simons, Paul P. T. Brons, Frank W.G. Leebeek, Daniëlle Meijer, Selene C M Schoormans, Britta A P Laros-van Gorkom, Waander L. van Heerde, Sandy Krouwel, Laurens Nieuwenhuizen, Dominique P M S M Maas, Nicole M. A. Blijlevens, Saskia E M Schols, Ferdows Atiq
Publikováno v:
Journal of Thrombosis and Haemostasis, 20(2), 316-327. Wiley-Blackwell Publishing Ltd
Journal of Thrombosis and Haemostasis, 20, 2, pp. 316-327
Journal of Thrombosis and Haemostasis, 20, 316-327
Journal of Thrombosis and Haemostasis, 20, 2, pp. 316-327
Journal of Thrombosis and Haemostasis, 20, 316-327
Contains fulltext : 248232.pdf (Publisher’s version ) (Open Access) BACKGROUND: An appropriate clinical diagnosis of von Willebrand disease (VWD) can be challenging because of a variable bleeding pattern and laboratory phenotype. Genotyping is a po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69cc08c282316528b8364c12e641bfea
https://pure.eur.nl/en/publications/ddb294bc-b7d6-4300-b9b9-372b6bb0b800
https://pure.eur.nl/en/publications/ddb294bc-b7d6-4300-b9b9-372b6bb0b800
Publikováno v:
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, 4, 343-346
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 2, Pp 343-346 (2020)
Research and Practice in Thrombosis and Haemostasis, 4, 2, pp. 343-346
Research and practice in thrombosis and haemostasis, 4(2), 343-346. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis, 4, 343-346
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 2, Pp 343-346 (2020)
Research and Practice in Thrombosis and Haemostasis, 4, 2, pp. 343-346
Research and practice in thrombosis and haemostasis, 4(2), 343-346. Wiley-Blackwell Publishing Ltd
Contains fulltext : 218309.pdf (Publisher’s version ) (Open Access) Congenital afibrinogenemia is a rare autosomal recessive disorder associated with an increased risk of hemorrhage, thrombosis, and obstetric complications. This case series of 4 pr
Autor:
Hendrika C A M Hazendonk, Tim Preijers, Frank W.G. Leebeek, R. A. A. Mathôt, Felix J. M. van der Meer, Iris van Moort, Britta A P Laros-van Gorkom, Marjon H. Cnossen, Laurens Nieuwenhuizen, Karina Meijer, Karin Fijnvandraat, Roger E. G. Schutgens
Publikováno v:
British Journal of Clinical Pharmacology, 87(6), 2602-2613. Wiley
British Journal of Clinical Pharmacology, 87, 2602-2613
British Journal of Clinical Pharmacology, 87(6), 2602-2613. Wiley-Blackwell Publishing Ltd
British journal of clinical pharmacology, 87(6), 2602-2613. Wiley-Blackwell
British Journal of Clinical Pharmacology, 87, 6, pp. 2602-2613
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, 87, 2602-2613
British Journal of Clinical Pharmacology, 87(6), 2602-2613. Wiley-Blackwell Publishing Ltd
British journal of clinical pharmacology, 87(6), 2602-2613. Wiley-Blackwell
British Journal of Clinical Pharmacology, 87, 6, pp. 2602-2613
British Journal of Clinical Pharmacology
Contains fulltext : 245042.pdf (Publisher’s version ) (Open Access) AIMS: Under- and, especially, overdosing of replacement therapy in haemophilia A patients may be prevented by application of other morphometric variables than body weight (BW) to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45ce2ecb1ea7f2d1442bad3d0e357fda
https://research.rug.nl/en/publications/b785c50f-97d8-4f39-b173-ebc413b6381b
https://research.rug.nl/en/publications/b785c50f-97d8-4f39-b173-ebc413b6381b
Autor:
Laura H. Bukkems, Lars L. F. G. Valke, Wideke Barteling, Britta A. P. Laros‐van Gorkom, Nicole M. A. Blijlevens, Marjon H. Cnossen, Waander L. van Heerde, Saskia E. M. Schols, Ron A. A. Mathôt
Publikováno v:
British journal of clinical pharmacology. Wiley-Blackwell
British Journal of Clinical Pharmacology, 88(6), 2757-2768. Wiley-Blackwell Publishing Ltd
British Journal of Clinical Pharmacology, 88, 2757-2768
British Journal of Clinical Pharmacology, 88, 6, pp. 2757-2768
British Journal of Clinical Pharmacology, 88(6), 2757-2768. Wiley-Blackwell Publishing Ltd
British Journal of Clinical Pharmacology, 88, 2757-2768
British Journal of Clinical Pharmacology, 88, 6, pp. 2757-2768
Contains fulltext : 251608.pdf (Publisher’s version ) (Open Access) AIMS: Prophylactic treatment of haemophilia A patients with factor VIII (FVIII) concentrate focuses on maintaining a minimal trough FVIII activity level to prevent bleeding. Howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cf3a8828040e7496d5991f4bc46b289
https://pure.amc.nl/en/publications/combining-factor-viii-levels-and-thrombinplasmin-generation(fbab51a5-698a-4d5d-9ea1-b3098a20f232).html
https://pure.amc.nl/en/publications/combining-factor-viii-levels-and-thrombinplasmin-generation(fbab51a5-698a-4d5d-9ea1-b3098a20f232).html